JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000413721.27409.e4
Speaker Schedule
    Back to Top | Article Outline

    Sunday, October 30, 2011

    Special Symposium on HIV Prevention, Care and Treatment from the PEPFAR Program in Africa

    Chairs: Alash'le Abimiku and Martine Etienne-Mesubi

    10:30 – 10:45—Izukanji Sikazwe, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Zambia

    Evaluation of AIDSRelief Facilities' Implementation of 2007 HIV Treatment Regimens After Introduction of the New Guidelines—AF1

    10:45 – 11:00—Nicaise Ndemi, Institute of Human Virology-Nigeria

    Pattern of Drug Resistant Mutations Among Nigerian Patients on PEPFAR NRTINNRTI Regimens—AF2

    11:00 – 11:15—Saidu Amed, Federal Ministry of Health, Nigeria

    Counseling and Testing and Access-to-Care Needs of Populations Most-at-Risk for HIV in Nigeria—AF3

    11:15 – 11:30—Phyllis Kanki, Harvard School of Public Health, Boston, MA

    HIV Drug Resistance in Nigeria, a Cost-Effective New Methodology—AF4

    11:30 – 11:45—Mary-Ann A. Etiebet, Institute of Human Virology-Nigeria

    High HIV-1 Prevalence, Risk Behaviors and Viral Loads Seen in Men Who Have Sex With Men Enrolled in a Community-Based Comprehensive HIV/AIDS Clinic in Nigeria—AF5

    11:45 – 12:00—Chuka J. Anude, Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD

    The HACART Study: Predictors of Immuno-Virologic Outcomes and Immuno-Virologic Discordance Among Adults on HIV Antiretroviral Therapy in Nigeria—AF6

    12:00 – 12:30—Lunch

    12:30 – 12:45—A. Maghimbi, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Tanzania

    Early Post – Anti- Retroviral Therapy Associated Mortality: Is It a Significant Problem That is Worthy Exploring? The Experience of AIDS Relief Tanzania—AF7

    12:45 – 1:00—Cyprien Baribwira, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Rwanda

    Mortality Following Initiation of ART in 2 AIDSRelief Supported District Hospitals in Rwanda—AF8

    1:00 – 1:15—V. J. Tepper, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD

    Relationship Between MEMSTM Adherence Rate, Pill Count and Viral Suppression Among HIV-Infected Children on Antiretroviral Therapy in Nigeria—AF9

    1:15 – 1:30—S. Ojoo, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Kenya

    Viral Response in HIV Infected Children Receiving Antiretroviral Therapy in The AIDSRelief Program in Kenya: A Retrospective Cross-Sectional Survey

    1:30 – 1:40—Robert R. Redfield, Institute of Human Virology William Blattner, Institute of Human Virology

    Closing Remarks

    Back to Top | Article Outline
    Track A

    Back to Top | Article Outline
    New Agents for Treatment of Viral Diseases

    Chairs: Robert Redfield and John Bartlett

    2:00—Robert Siliciano

    Understanding How HAART Works—101

    2:20—James Arthos

    HIV-1 gp120 Interactions With the Gut Homing Receptor Integrin α4β7 on CD4+ T Cells—103

    2:40—David Thomas

    New Treatment for Hepatitis C Virus Infection—104

    3:00—John Bartlett

    New Treatments for HIV Infection—105

    3:20—Break – 15 minutes

    3:35—Robert Redfield

    Targeting CCR5 Density for Treatment and Prevention—106

    3:55—Angus Dagleish

    The Potential Role of Antibodies to the C5 Domain in gp120 Mitigating Generalized Immune Activation Associated With HIV-1 Infection

    4:15—Paolo Lusso

    Interleukin-7 As an Immune Reconstitution Agent in HIV-1 Infection: Ex Vivo and in Vivo Protective Effects on CD4+ T Cells—107

    4:35—John Moore

    Towards Coitally-Independent Microbicides: Studies with Vaginal Rings and Silicone-Based Gel Delivery Systems—108

    4:55—Leonid Margolis

    HIV-1 Transmission from Semen to the Female Genital Tract and Its Prevention, as Seen in an ex vivo Tissue Model—109

    5:30 – 7:30—Welcome Reception, Marriott Hotel

    Back to Top | Article Outline

    Monday, October 31, 2011

    Special Lecture

    8:30—Paul Offit

    Hard Knocks: Communicating Science to the Public—110

    Back to Top | Article Outline
    Track B

    Back to Top | Article Outline
    Mechanisms for Vaccine Protection Against HIV

    Chairs: Jose Esparza and William Hall

    9:00— Morgane Bomsel

    Mucosal Gp41- Virosome Vaccine Protects Rhesus Macaques from Multiple Vaginal Challenges with Heterologous SHIV

    9:20—Leo Stamatatos

    Interactions Between HIV Env and Germline Versions of bNAbs—111

    9:40—George Lewis

    Diversity of Specificity and Function Among Human Antibodies to Transitional Epitopes Altered by CD4 Binding to the HIV-1 Env Glycoprotein—112

    10:00—Barton Haynes

    Protective Antibody Responses in HIV Vaccinees and Infected Subjects

    10:20—Break – 15 minutes

    10:35—Nelson Michael

    Immune Correlates of Infection Risk in the Thai Phase III ALVAC-HIV/AIDSVA-B/E Prime Boost Study—113

    10:55—Susan Zolla-Pazner

    Role of Vaccine-Induced V2 Antibodies in Protection from HIV Infection of Recipients in the RV144 Clinical Vaccine Trial—114

    11:15—David Montefiori

    Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection—116

    11:35—Dan Barouch

    Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenger in Rhesus Monkeys—122

    Back to Top | Article Outline
    Special Lecture

    11:55—Anthony Fauci

    Ending the HIV/AIDS Pandemic: A Realistic Goal—117

    12:30 – 2:00—Lunch

    Back to Top | Article Outline
    Special Lecture

    2:00—Michel Nussenweig

    The Neutralizing Antibody Response to HIV

    Back to Top | Article Outline
    Track C

    Back to Top | Article Outline
    Evaluating Candidate HIV Vaccines

    Chairs: Gunnel Biberfeld and Arnaldo Caruso

    2:30—Jonathan Gershoni

    Deep Panning – High Resolution Profiling Antibody Specificities—119

    2:50—Peter Kwong

    Structural Immunology and Vaccine Development—120

    3:10—Norman Letvin

    Effect of Activating KIR Copy Number Variation on NK Cell Containment of SIV Replication in Rhesus Monkeys—121

    3:30—George Pavlakis

    DNA and Protein Vaccination via Electroporation Confers Protection Against Mucosal Challenge with Heterologous SIVsmE660—115

    3:50—Marjorie Robert-Guroff

    Vaccine-Elicited Antibodies Contribute to Protective Efficacy, Including Mucosal Antibodies, Correlated with Delayed SIV Acquisition—123

    4:10—Harriet Robinson

    GeoVax HIV/AIDS Vaccine Program, Preclinical and Clinical Studies—124

    4:30—Break – 10 minutes

    4:40—James Mullins

    The Dynamics of Early HIV Infection and a Consequent New Approach to Vaccine Design—125

    5:00—Gary Nabel

    Broadly Neutralizing HIV Abs: Gains and Losses in Translation—126

    Back to Top | Article Outline
    Special Lecture

    5:20—Nicoli Nattrass

    Fighting AIDS Denialism—127

    6:00 – 8:00—Poster Reception, Marriott Hotel

    Back to Top | Article Outline

    Tuesday, November 1, 2011

    Special Lecture

    8:30—Peter Palese

    Toward a Universal Influenza Virus Vaccine—128

    Back to Top | Article Outline
    Track D

    Back to Top | Article Outline
    Interactions of HIV and Host Cells

    Chairs: Anthony DeVico and Luigi Buonaguro

    9:00—Ashley Haase

    Live Attenuated Vaccine Induced Mucosal Antibodies and Early Events in the SIV-NHP Model of HIV-1 Transmission to Women—129

    9:20—Thomas Hope

    Neutralizing and Non-Neutralizing HIV-Specific Antibodies Hinder the Movement of Virus in Fresh Human Cervical Mucus—130

    9:40—Eric Hunter

    Characteristics of Transmitted Founder Viruses: Impact of Transmitting Partner Genetics—131

    10:00—Donald Forthal

    Antibodies and Fc Receptors: Their Potential Impact on HIV Infection—132

    10:20—Break – 15 minutes

    10:35—Mario Stevenson

    Factors Influencing HIV-Macrophage Interplay

    10:55—Rick Bushman

    HIV DNA Integration: Mechanism and Consequences—134

    11:15—Paul Bieniasz

    Tetherin - Keeping Virions on a Leash—135

    11:35—Alain Lafeuillade

    A Roadmap Towards HIV Infection Cure—136

    11:55—Irvin Chen

    Stem Cell Therapy for HIV Disease—137

    12:15—Andrea Cerutti

    A Novel Innate Pathway for Antibody Diversification and Production—102

    12:35 – 2:00—Lunch

    Back to Top | Article Outline
    Special Lecture

    2:00—Diane Griffin

    Mechanisms of Virus Clearance from the Nervous System—138

    Back to Top | Article Outline
    Track E

    Back to Top | Article Outline
    Immune Mechanisms Controlling Viral Disease

    Chairs: Guido Poli and Isaac Witz

    2:30—Ed Berger

    Epitope Masking Mechanism Within the HIV-1 Env Trimer Analyzed by Functional Subunit Complementation—139

    2:50—Guido Silvestri

    Antiviral Immune Responses, Chronic Immune Activation, and Pattern of Infected Cells in AIDS Pathogenesis: A Lesson from Non-Human Primate Models—140

    3:10—Mario Roederer

    The Role of T Memory Stem Cells: Pathogenesis and Vaccines—141

    3:30—David Pauza

    Cause and Consequence of CD4-Negative T Cell Depletion During HIV Disease—142

    3:50—Break – 10 minutes

    4:00—Paolo Rossi

    Pediatric HIV Infection: Forging a Path Towards Therapeutic Vaccination—143

    4:20—Judy Lieberman

    The Cytosolic Exonuclease TREX1 Digests HIV Reverse Transcripts to Avoid Triggering an Antiviral Interferon Response in T Cells and Macrophages—144

    4:40—Warner Greene

    Pyroptosis and HIV-Induced CD4 T Cell Death—145

    5:00—Samuel Broder

    Therapy Against HIV-1/AIDS: Past, Present, Future

    6:30—Institute of Human Virology Lifetime Achievement Awards Reception

    Back to Top | Article Outline
    Special Speaker

    Samuel Broder, M.D., Director, NCI (retired)

    Bernadine Healy: The Fundamental Truths of Her Life

    7:30 Gala Dinner

    Back to Top | Article Outline

    Wednesday, November 2, 2011

    Track F

    Back to Top | Article Outline
    Virally-Associated Malignant Diseases

    Chairs: William Blattner and Franco Buonaguro

    8:30—Genoveffa Franchini

    Retooling the Macaque Model to Evaluate the Relative Efficacy of HIV Vaccine Candidates—154

    8:50—Bassam Badran

    CD4+CD25+CD127low Regulatory T Cells: MicroRNA Signature and Effect of Valproate on microRNA and FOXP3 Expression Levels in CD4+CD25- T Cells—155

    9:10—Clement Adebamowo

    Developing AIDS Associated Cancer Research in Africa—147

    9:30—Robert Yarchoan

    Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Related Multicentric Castleman's Disease (MCD) and Inflammatory Cytokine Syndrome (KICS): Pathogenesis and Treatment—148

    9:50—Anna Linda Zignego

    Hepatitis C Virus (HCV)-Related Lymphoproliferative Disorders—149

    10:10—Jim Goedert

    Update on Malignancies Among People with HIV/AIDS—150

    10:30—Break 15 minutes

    10:45—Sam Mbulaiteye

    Virally Associated Malignancies in the HIV Era—151

    11:05—Ali Bazarbachi

    Can We Cure HTLV-I Associated Adult T Eell Leukemia Lymphoma?—152

    11:25—K. T. Jeang

    Transformation of Human Cells by HTLV-1 Tax—153

    11:45—Patrick Moore

    What Happens When Your Viral Flora Gives You Cancer?—156

    Back to Top | Article Outline
    Special Lecture

    12:05—Jay A. Berzofsky

    Strategies for Anti-Cancer Immunotherapy Using Vaccines and Blockade of Negative Regulation—157

    © 2012 Lippincott Williams & Wilkins, Inc.